Benitec Biopharma Reports 100% Response Rate in Interim BB-301 Phase 1b/2a Trial Results
Bitget2026/10/28 12:02- Benitec Biopharma announced positive interim Phase 1b/2a results for BB-301 in patients with swallowing difficulties caused by oculopharyngeal muscular dystrophy.
- All nine treated patients responded to therapy, with low-dose improvements sustained through 12 months.
- High-dose treatment showed greater improvements in throat emptying and functional swallowing capacity than the low dose at three months.
- No serious adverse events were reported; a pivotal study is planned for mid-2027.
- Results are available in a poster accepted as a late-breaking abstract at the European Society of Gene and Cell Therapy annual congress.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
